Positive Outlook for Carl Zeiss Meditec

Friday, 17. July 2009 07:22
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this

JENA/Germany - 17 July 2009.
Carl Zeiss Meditec AG, listed in the TecDAX at the German Stock
Exchange, is to continue the path of focus and growth initiated a
year ago with Dr. Michael Kaschke (52) as President and CEO. Dr.
Kaschke has resigned his suspended membership of the Supervisory

"The entire Supervisory Board is impressed by the results achieved.
With a targeted strategic direction, it has proved possible under Dr.
Kaschke's leadership to keep the company on a path of success and
growth even in these difficult economic times. For that reason, we
will continue to put our trust in continuity," explained Dr. Markus
Guthoff, Chairman of the Supervisory Board of Carl Zeiss Meditec AG.

"With a targeted focus on innovation, customer orientation and growth
markets, we are posting pleasing results even in the context of the
current economic situation. We will continue to invest in
future-oriented topics. We can confirm our statement that Carl Zeiss
Meditec will continue to grow while keeping the profitability stable
and increasing it in the medium term. Compared to last year, we
anticipate revenue growth of at least 5 percent in this current
adverse year," concluded Dr. Michael Kaschke, President and CEO of
Carl Zeiss Meditec AG.

Press contacts:
Eva Sesselmann
Director Corporate Communications
Carl Zeiss Meditec AG
Göschwitzer Straße 51-52
07745 Jena
Phone: +49 3641 220-331
Fax: +49 3641 220-112
E-mail: press@meditec.zeiss.com
Patrick Kofler
Director Investor Relations
Carl Zeiss Meditec AG
Göschwitzer Straße 51-52
07745 Jena
Phone: +49 3641 220-106
Fax: +49 3641 220-117
E-mail: investors@meditec.zeiss.com

Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is listed in the Tec-DAX
of the Deutsche Börse and is one of the world's leading medical
technology suppliers.
The company supplies innovative technologies and application-oriented
solutions designed to help doctors improve the quality of life of
their patients. It provides complete packages of solutions for the
diagnosis and treatment of eye diseases - including implants and
consumable materials. The company creates innovative visualisation
solutions in the field of microsurgery. Carl Zeiss Meditec's medical
technology portfolio is rounded off by promising future technologies
such as intraoperative radiation therapy.
In the 2007/2008 (30 September) financial year the 2,100 employees
generated revenue of approximately 600 EUR million. The head office
of Carl Zeiss Meditec is in Jena, Germany. The company has
subsidiaries in Germany and abroad; more than 50 percent of its
employees are based in the USA, Japan, Spain and France.
35 percent of Carl Zeiss Meditec shares are in free float. The
remaining 65 percent are held by Carl Zeiss AG, one of the world's
leading groups engaged in the optical and opto-electronics industry.
The five independently managed business units of Carl Zeiss AG
operate in the future-oriented markets of "Medical and Research
Solutions", "Industrial Solutions" and "Lifestyle Products". The head
office of Carl Zeiss AG is in Oberkochen, Germany. In the 2007/08
financial year (balance sheet date 30 September) the group posted
sales of ¤ 2.7 billion. Carl Zeiss has a total workforce of about
13,000 in over 30 countries, over 8,000 of them in Germany.
Further information: http://www.meditec.zeiss.com

--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share,
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in
Frankfurter Wertpapierbörse;
Related Links: Carl Zeiss Meditec AG
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.